Reshoring APIs and Scaling Continuous Manufacturing for Generic Drug Supply

Reshoring APIs and Scaling Continuous Manufacturing for Generic Drug Supply

Generic medicines account for the vast majority of prescriptions in the U.S., yet much of their underlying supply chain remains heavily dependent on foreign-sourced active pharmaceutical ingredients (APIs). As concerns around drug shortages and supply chain resilience intensify, attention is shifting upstream toward how APIs are manufactured, where they are sourced, and what it will take to rebuild domestic production capacity. At the same time, advanced manufacturing approaches like continuous flow are gaining traction as a way to improve efficiency, safety, and cost competitiveness in a traditionally low-margin market.

In this episode of Off Script, we spoke with Brian Doty, vice president of R&D and programs at the API Innovation Center (APIIC), about the structural challenges facing generic drug manufacturing and the role advanced technologies could play in addressing them. The conversation explores why API supply is often the cause of downstream drug shortages, the technical and economic limitations of traditional batch processing, and how continuous manufacturing can reduce process steps, improve control, and enable safer production. Doty also discusses the practical barriers to adoption as well as the growing role of FDA engagement programs and policy incentives in accelerating change.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(129)

Accelerating Biopharma Manufacturing Through Integrated Automation

Accelerating Biopharma Manufacturing Through Integrated Automation

Biopharmaceutical manufacturers are facing mounting pressure to scale production faster while maintaining quality and operational reliability due to the ever-expanding pipeline of therapies. Meanwhile...

30 Jun 21min

The Future of Global Biopharma Manufacturing Networks

The Future of Global Biopharma Manufacturing Networks

Amid ongoing geopolitical uncertainty, regional manufacturing initiatives, and evolving supply chain risks reshaping the pharmaceutical industry, manufacturers are rethinking how biologics are produce...

23 Jun 12min

Building Flexibility into Biopharma Manufacturing

Building Flexibility into Biopharma Manufacturing

As biopharma pipelines become more complex and market conditions continue to evolve, manufacturers are rethinking how they scale capacity, deploy capital, and build supply chains. The industry’s focus...

16 Jun 19min

How Biocatalysis Is Changing Pharma Manufacturing

How Biocatalysis Is Changing Pharma Manufacturing

Interest in macrocyclic peptides (MCPs) continues to grow, which means manufacturers are facing mounting pressure to develop production methods capable of supporting commercial-scale demand of these m...

9 Jun 19min

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part Two

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part Two

As peptide therapeutics become larger, more complex, and increasingly purity-sensitive, manufacturers are confronting a new layer of execution challenges. Long-chain peptides introduce compounding sca...

2 Jun 20min

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part One

How Peptide Development Complexity Is Reshaping CDMO Partnerships: Part One

Peptide pipelines continue to expand globally, and pharmaceutical companies are increasingly turning to CDMOs earlier in the development lifecycle to help manage growing technical and operational comp...

26 Mai 20min

Solutions Spotlight: Managing Chloramines in Pharmaceutical Water Systems

Solutions Spotlight: Managing Chloramines in Pharmaceutical Water Systems

As municipal water utilities increasingly shift from free chlorine to chloramine disinfection strategies, pharmaceutical manufacturers are facing new challenges in maintaining consistent, high-purity ...

22 Mai 17min

Can CDMO-to-CDMO Collaboration Simplify Drug Development?

Can CDMO-to-CDMO Collaboration Simplify Drug Development?

Amid increasing complexity in the drug development landscape, CDMOs are exploring new ways to streamline the path from early-stage formulation through commercial manufacturing. Rather than operating i...

19 Mai 19min

Populært innen Politikk og nyheter

giver-og-gjengen-vg
aftenpodden
aftenpodden-usa
fotballpodden-2
forklart
stopp-verden
popradet
rss-gukild-johaug
det-store-bildet
nokon-ma-ga
hanna-de-heldige
rss-espen-lee-usensurert
dine-penger-pengeradet
rss-ness
lydartikler-fra-aftenposten
rss-penger-polser-og-politikk
aftenbla-bla
e24-podden
frokostshowet-pa-p5
chit-chat-med-helle